I would say this decision at this stage would affect their near term revenue more. With the old ruling, if I understand it correctly, if cu64 gets approved they would have 3 years where they would have the majority of hospitals administering their imaging agent due to the the expiry of the pass through reimbursement rule for the other older imaging agents.
It will expand the desire for pharma companies to acquire cu64 though, as it allows them to value the asset on patent life and quality of the agent.
Note cu6 has this as non PS whereas TLX has put it as PS.
Ann: CMS final rule on radio-diagnostic reimbursement policy, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.52 |
Change
0.130(5.44%) |
Mkt cap ! $810.1M | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.54 | $2.37 | $5.141M | 2.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6820 | $2.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.52 | 3500 | 1 |
View Market Depth
| Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |